– A Global Awareness Day for a Rare Life-Threatening Condition –
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--May 16, 2018--
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage
pharmaceutical company focused on the discovery, development, and
commercialization of small molecule protease inhibitors, today announced
recognition of patient organizations from around the world holding a
global awareness day for the condition hereditary angioedema (HAE). In
support of this annual awareness day, KalVista is sponsoring and
attending the HAE Global Conference to be held in Vienna, Austria on May
“Our sponsorship of the HAE Global Conference reflects our commitment to
developing a best-in-class oral therapy, which we believe could
meaningfully improve the quality of life for patients,” said Andrew
Crockett, Chief Executive Officer of KalVista. “We look forward to
interacting with patients and caregivers at the Conference. We also
intend to provide an update on our HAE portfolio in the next few months.”
“HAE is a rare genetic disorder that causes swelling to various parts of
the body, and can be fatal when the swelling affects the throat due to
the risk of suffocation,” explains Mr. Henrik Balle Boysen, Executive
Director of HAEi, the international patient organization leading the
day. “Global awareness initiatives such as the hae day :-) are necessary
in order to help patients receive faster diagnosis and care to manage
As part of the awareness initiatives HAEi introduces “Support Family
Testing” tools on the organization’s campaign website www.haeday.org.
“As HAE is a hereditary disorder, it is very important to have other
family members tested. To help patients in this process we have
developed two documents for patients and one for physicians,” says Mr.
HAEi is a global organization dedicated to raising awareness of C1
inhibitor deficiencies as HAE patients have a defect in the gene that
controls a blood protein called C1-inhibitor, and therefore the disorder
is also commonly referred to as C1-inhibitor deficiency. HAEi is a
non-profit international network of presently 61 national HAE patient
organizations spread across the globe.
“HAEi is established to promote co-operation, co-ordination and
information sharing between HAE specialists and national HAE patient
associations in order to help facilitate the availability of effective
diagnosis and management of C1 inhibitor deficiencies throughout the
world. Our purpose is to join the efforts and experience of the global
HAE community to achieve optimal standards of care and treatment for all
those patients affected by C1 inhibitor deficiencies,” says Mr. Balle
The 2018 hae day :-) coincides with patients, relatives, caregivers, and
people from the industry walking part of the ancient pilgrimage
Jakobsweg route though Vienna, Austria where the fourth HAE Global
Conference is taking place.
About KalVista Pharmaceuticals, Inc.
Pharmaceuticals, Inc. is a pharmaceutical company focused on the
discovery, development, and commercialization of small molecule protease
inhibitors for diseases with significant unmet need. The initial focus
is on inhibitors of plasma kallikrein, which is an important component
of the body’s inflammatory response and which, in excess, can lead to
increased vascular permeability, edema and inflammation. KalVista has
developed a proprietary portfolio of novel, small molecule plasma
kallikrein inhibitors initially targeting hereditary angioedema (HAE)
and diabetic macular edema (DME). The Company has created a structurally
diverse portfolio of oral plasma kallikrein inhibitors and is advancing
multiple drug candidates into Phase 1 clinical trials for HAE.
KalVista’s most advanced program, an intravitreally administered plasma
kallikrein inhibitor known as KVD001, has successfully completed its
first-in-human study in patients with DME and began a Phase 2 clinical
trial in 2017.
For more information, please visit www.kalvista.com.
This press release contains
"forward-looking" statements within the meaning of the safe harbor
provisions of the U.S. Private Securities Litigation Reform Act of 1995.
Forward-looking statements can be identified by words such as:
"anticipate," "intend," "plan," "goal," "seek," "believe," "project,"
"estimate," "expect," "strategy," "future," "likely," "may," "should,"
"will" and similar references to future periods. These statements are
subject to numerous risks and uncertainties that could cause actual
results to differ materially from what we expect. Examples of
forward-looking statements include, among others, available funding, our
cash runway and future clinical trial timing and results. Further
information on potential risk factors that could affect our business and
its financial results are detailed in the annual report on Form 10-K
filed on July 27, 2017, our most recent Quarterly Report on Form 10-Q,
and other reports as filed from time to time with the Securities and
Exchange Commission. We undertake no obligation to publicly update any
forward-looking statement, whether written or oral, that may be made
from time to time, whether as a result of new information, future
developments or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180516005165/en/
Source: KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc.
Leah Monteiro, 857-999-0808
Corporate Communications & Investor Relations